Biofrontera AG logo

Biofrontera AG (B8FKd)

Market Open
CBOE CBOE
- Market Cap
- P/E Ratio
- Div Yield
- Volume
0 Eps
Want to track B8FKd and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

B8FKd is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on CBOE (EUR).

Biofrontera AG (B8FKd) FAQ

On which exchange is it traded?

Biofrontera AG is listed on CBOE.

What is its stock symbol?

The ticker symbol is B8FKd.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Biofrontera AG ever had a stock split?

No, there has never been a stock split.

Biofrontera AG Profile

Specialty Retail Industry
Consumer Discretionary Sector
Pilar de la Huerta Martinez CEO
CBOE Exchange
- ISIN
DE Country
97 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Biofrontera AG is a biopharmaceutical company that is focused on the research, development, and commercialization of dermatological products. Established in 1997, the company has carved out a niche in the dermatology sector by bringing innovative solutions to the market, particularly for the treatment of skin conditions such as actinic keratoses, field cancerization, and squamous cell carcinoma. Biofrontera AG has established a strategic collaboration and partnership with Maruho Co., Ltd., enhancing its reach and development capabilities. Headquartered in Leverkusen, Germany, the company continues to focus on addressing unmet medical needs in dermatology.

Products and Services

  • Ameluz
  • Ameluz is a treatment developed by Biofrontera AG for mild and moderate actinic keratoses on the face and scalp. Actinic keratoses are rough, scaly patches on the skin, caused by years of sun exposure, which can potentially lead to skin cancer if left untreated. Ameluz is used in photodynamic therapy (PDT), a process that involves applying the medication to the lesions and then exposing them to a light source, leading to the destruction of the affected cells.

  • BF-RhodoLED Lamp
  • The BF-RhodoLED lamp is specifically designed to work in conjunction with Ameluz for the effective treatment of actinic keratoses through photodynamic therapy (PDT). This state-of-the-art lamp emits light at a precise wavelength, activating the applied drug and facilitating the targeted destruction of precancerous cells without harming the surrounding healthy skin.

  • RhodoLED XL
  • RhodoLED XL represents an advancement in the treatment of actinic keratoses, particularly designed for patients with multiple interspersed lesions. This larger version of the BF-RhodoLED lamp allows for the treatment of broader areas, making the PDT process more efficient and convenient for patients with extensive skin damage due to sun exposure.

  • Belixos
  • Belixos is a part of Biofrontera AG’s medical skin care range, specifically formulated for irritated and sensitive skin. This product line leverages the power of natural ingredients and scientific research to provide soothing relief and effective care for a variety of skin problems. Belixos products aim to calm, repair, and protect the skin, offering a gentle yet effective option for daily skincare.

Contact Information

Address: Hemmelrather Weg 201
Phone: 49 214 87 63 2 0